

**Notes of: Meeting of the Northern and Eastern Devon Formulary Interface Group
Thursday 11th June 2015: 9:00am – 11:00am. Old Heathcoat's School, Tiverton**

Present	Tawfique Daneshmend (TD), Consultant Gastroenterologist - Chair	RD&E
	Carol Albury (CA), Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Iain Carr (IC), Medicines Optimisation Pharmacist	NEW Devon CCG
	Amanda Gulbranson, Clinical Effectiveness Lead	DPT
	Andrew Harrison (AH), GP, The South Lawn Medical Practice	NEW Devon CCG
	Ali Hodgetts (AH), Clinical Pharmacy Manager	RD&E
	Matt Howard (MH), Clinical Evidence Manager	NEW Devon CCG
	Simon Kay (SK), GP	NEW Devon CCG
	Carole Knight (CK), Formulary Pharmacist	NDDH
	Carl Peacock (CP), Medicines Optimisation Pharmacist	NEW Devon CCG
	Sam Smith (SS), Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Petrina Trueman (PT), Joint Formularies Pharmacist	NEW Devon CCG
	Ben Waterfall (BW), GP	NEW Devon CCG
	Carol Webb (CW), Joint Formularies Technician	NEW Devon CCG
Apologies	Beverly Baker (BB), Non-Medical Prescribing Lead	NEW Devon CCG
	Niall Ferguson (NF), Director of Pharmacy	NDDH
	Tracey Foss (TF), Chief Pharmacist	RD&E
	Susie Harris (SHa), Consultant, Elderly Care	RD&E
	Stuart Kyle (SKy), DTC Chair / Consultant Rheumatologist	NDDH
	Darunee Whiting (DW), GP, Northam Surgery	NEW Devon CCG

1. Welcome and Apologies – noted above
Declarations of interest: no interests were declared

2. **Notes of previous meeting:**
The notes of the meeting of 9th April 2015 were agreed.

Action list from the previous minutes, not on the agenda

- **CKD and apixaban:** the South West Cardiovascular Strategic Clinical Network has updated their guidance on NOACs for the prevention of stroke and AF. The formulary guidance has been amended in the light of this. It was noted that apixaban is the preferred anticoagulant in the NICE CG 182 Chronic kidney disease.

3. **Review: Chapter 7 Obs & Gynae**

This chapter has been reviewed; the urinary tract disorders section is to be completed.

- 7.3 Contraception guidance: this information has been updated
- 7.3.1: the products in this section have been ordered such that the less costly products are first-line. The following products have been removed:
 - Ovranelle®
 - Microgynon® 30 (and ED)
 - Sunya 20/75®
 - Mercilon®
 - Katya 30/75®

- Marvelon® (to remain as an option for severe acne)
- Noriday

The changes to this section were agreed, the formulary to be updated

4. **Lipids**

The main recommendations in the revised NICE Clinical Guideline 181, published in July 2014, have been incorporated into the formulary guidance. A question was raised regarding doing liver function tests after 3 months, as you would on a patient starting statins, on patients switching from simvastatin to atorvastatin.

Action: to contact the pathology group, Richard Croker and Darunee Whiting, regarding this.

PT

Omacor® is no longer recommended, it was agreed to remove this. It was also agreed to remove atorvastatin chewable tablets.

Formulary to be updated with this revised guidance.

5. **Consideration of Eppinix® XL for addition to the formulary**

Eppinix® XL is a branded version of ropinirole MR, which although used widely is not currently in the North and East Devon Formulary. Ropinirole MR is included in the South and West Devon Formulary. Eppinix® XL is half the cost and would give savings of approximately £71,000 annually for the CCG.

Assurance was given by Medicines Optimisation that the products above demonstrated bioequivalence.

Specialists have been contacted and indicated that they could foresee no significant consequences with the proposal.

It was noted that the hospital purchasing contract preferred products are different from the formulary choices.

It was agreed to add Eppinex® XL to the formulary

6. **Stavelo® replacement**

It is proposed that Stavelo® is replaced in the formulary by Sastravi®. This would give an approximate saving of £55,000 across Devon over 12 months.

Assurance was given by Medicines Optimisation that the products above demonstrated bioequivalence.

Specialists have been contacted regarding this change

It was agreed to add Sastravi® into the formulary and remove Stavelo®.

7. **ADHD Shared care guidelines**

These guidelines are to be discussed at the South and West Devon Formulary meeting on the 8th July, with input from the specialists. An invitation to attend this meeting was extended and the members were asked to give any comments or concerns on the content of these guidelines.

AG noted that the consultants have no concerns regarding the change from Concerta® XL to Xenidate® XL.

AG noted that communication has been received confirming that Xenidate is formulated so as to reduce the risk of abuse

The members indicated agreement to these guidelines being discussed and agreed at the South and West Formulary meeting in July.

8. **NICE TA336 Empagliflozin**

This NICE TA was issued in March 2015 and empagliflozin has been added to the formulary. Its position in the treatment of type 2 diabetes has been added to the current guidance in the formulary. It was noted that NICE are due to issue revised guidance on the treatment of type 2 diabetes in August and that the recommendations will be reviewed at that time.

9. **Gluten free: 9.4.1 Foods for special diets**

There is currently no guidance in the formulary in this section. It was acknowledged that there needs to be guidance to support prescribers in their prescribing of gluten free products. The current guidance in the South and West formulary to be looked at together with the new guidelines given by PresQuip and some guidance to be written for the formulary.

Action: prescribing guidelines for gluten free foods to be written

SS

10. **Recent drugs decisions:**

These were noted

11. **MHRA Drug Safety Update, April and May:**

April: to put into the formulary the notes on hydroxyzine and QT interval.

May: this was noted, nothing to add to the formulary

Next meeting: Thursday 13th August 2015

Northern & Eastern Formulary – Action Log

Date	Action	Responsible	Completed
Apr 15	Low dose aspirin and PPI for all patients <ul style="list-style-type: none"> to look further at this and to report back any information 	TD	
June 15	LFT testing when changing from simvastatin to atorvastatin	PT	
June 15	Gluten free prescribing guidelines	SS	